44.  American College For Advancement in Medicine, Docket No. C-3882 (final consent July 13, 1999)

Respondent: American College for Advancement in Medicine (ACAM)

Type:  Deceptive Health Claims

ACAM advertised and promoted its non-surgical EDTA "chelation therapy" online. ACAM allegedly made false and unsubstantiated claims that its therapy was effective in treating atherosclerosis.

On July 13, 1999, the Commission announced its final approval of an administrative settlement with respondents. Under this consent agreement, ACAM is prohibited from representing -- absent competent and reliable scientific information -- that chelation therapy is effective in treating atherosclerosis or any human circulatory disease.

http:/www.ftc.gov/opa/1998/9812/acam.htm (press release - proposed consent)